The global opioid use disorder (OUD) market size is projected to reach USD 4.50 billion by 2026, exhibiting a CAGR of 10.8% during the forecast period. Increasing addiction to opioids across the globe will be the central force driving the growth of this market, shares Fortune Business Insights™ in its recent report, titled “Opioid Use Disorder (OUD) Market Size, Share & Industry Analysis, By Drug Class (Buprenorphine, Methadone, and Naltrexone), By Route of Administration (Oral, and Parenteral), By Distribution Channel (Hospital Pharmacies, Retails Pharmacies & Stores, and Online Pharmacies), and Regional Forecast, 2019-2026”.
Click here to get the short-term and long-term impact of COVID-19 on this Opioid Use Disorder (OUD) Market.
Please visit: https://www.fortunebusinessinsights.com/opioid-use-disorder-oud-market-102674
Detailed Table of Content:
- Introduction
1.1. Research Scope
1.2. Market Segmentation
1.3. Research Methodology
1.4. Definitions and Assumptions
- Executive Summary
- Market Dynamics
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
- Key Insights
4.1. Pipeline Analysis
4.2. New Product Launches
4.3. Statistics of Opioid Use Disorder
4.4. Industry Developments Such as Mergers, Acquisitions, and Collaborations
- Global Opioid Use Disorder (OUD) Market Analysis, Insights and Forecast, 2015-2026
5.1. Key Findings / Summary
5.2. Market Analysis, Insights and Forecast – By Drug Class
5.2.1. Buprenorphine
5.2.2. Methadone
5.2.3. Naltrexone
5.3. Market Analysis, Insights and Forecast – By Route of Administration
5.3.1. Oral
5.3.2. Parenteral
5.4. Market Analysis, Insights and Forecast – By Distribution Channel
5.4.1. Hospitals Pharmacies
5.4.2. Retail Pharmacies & Stores
5.4.3. Online Pharmacies
5.5. Market Analysis, Insights and Forecast – By Region
5.5.1. North America
5.5.2. Europe
5.5.3. Asia Pacific
5.5.4. Rest of the World
- North America Opioid Use Disorder (OUD) Market Analysis, Insights and Forecast, 2015-2026
6.1. Key Findings / Summary
6.2. Market Analysis – By Drug Class
6.2.1. Buprenorphine
6.2.2. Methadone
6.2.3. Naltrexone
6.3. Market Analysis – By Route of Administration
6.3.1. Oral
6.3.2. Parenteral
6.4. Market Analysis – By Distribution Channel
6.4.1. Hospitals Pharmacies
6.4.2. Retail Pharmacies & Stores
6.4.3. Online Pharmacies
6.5. Market Analysis – By Country
6.5.1. U.S.
6.5.2. Canada